CY1124073T1 - Πολυμερη συνδεσης πρωτονιου για χορηγηση απο του στοματος - Google Patents

Πολυμερη συνδεσης πρωτονιου για χορηγηση απο του στοματος

Info

Publication number
CY1124073T1
CY1124073T1 CY20211100141T CY211100141T CY1124073T1 CY 1124073 T1 CY1124073 T1 CY 1124073T1 CY 20211100141 T CY20211100141 T CY 20211100141T CY 211100141 T CY211100141 T CY 211100141T CY 1124073 T1 CY1124073 T1 CY 1124073T1
Authority
CY
Cyprus
Prior art keywords
proton
oral administration
binding polymer
animal
treating
Prior art date
Application number
CY20211100141T
Other languages
English (en)
Inventor
Gerrit Klaerner
Eric F. Connor
Randi K. GBUR
Matthew J. Kade
Paul H. KIERSTEAD
Jerry M. Buysse
Michael J. COPE
Kalpesh N. BIYANI
Son H. Nguyen
Scott M. TABAKMAN
Original Assignee
Tricida Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tricida Inc. filed Critical Tricida Inc.
Publication of CY1124073T1 publication Critical patent/CY1124073T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/02—Alkylation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C08F226/04—Diallylamine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F26/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F26/02—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F26/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F26/02—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C08F26/04—Diallylamine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F271/00—Macromolecular compounds obtained by polymerising monomers on to polymers of nitrogen-containing monomers as defined in group C08F26/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2810/00—Chemical modification of a polymer
    • C08F2810/20—Chemical modification of a polymer leading to a crosslinking, either explicitly or inherently
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2333/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers
    • C08J2333/24—Homopolymers or copolymers of amides or imides
    • C08J2333/26—Homopolymers or copolymers of acrylamide or methacrylamide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Φαρμακευτικές συνθέσεις για θεραπεία και μέθοδοι θεραπείας ζώου, συμπεριλαμβανομένου ανθρώπου, και μέθοδοι παρασκευής τέτοιων συνθέσεων. Οι φαρμακευτικές συνθέσεις περιέχουν εγκάρσια συνδεδεμένα πολυμερή αμίνης και μπορεί να χρησιμοποιηθούν, για παράδειγμα, για να θεραπεύονται ασθένειες ή άλλες μεταβολικές καταστάσεις στις οποίες απομάκρυνση πρωτονίων ή/και χλωριούχων ιόντων από τη γαστρεντερική οδό θα παρέχει φυσιολογικά οφέλη όπως κανονικοποίηση συγκεντρώσεων όξινου ανθρακικού του ορού και του pΗ αίματος σε ένα ζώο, συμπεριλαμβανομένου ανθρώπου.
CY20211100141T 2014-12-10 2021-02-19 Πολυμερη συνδεσης πρωτονιου για χορηγηση απο του στοματος CY1124073T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462090287P 2014-12-10 2014-12-10
PCT/US2015/065041 WO2016094685A1 (en) 2014-12-10 2015-12-10 Proton-binding polymers for oral administration
EP15823049.0A EP3229816B1 (en) 2014-12-10 2015-12-10 Proton-binding polymers for oral administration

Publications (1)

Publication Number Publication Date
CY1124073T1 true CY1124073T1 (el) 2022-05-27

Family

ID=55080167

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20201100400T CY1122928T1 (el) 2014-12-10 2020-04-30 Πολυμερη συνδεσης πρωτονιου για χορηγηση απο του στοματος
CY20211100141T CY1124073T1 (el) 2014-12-10 2021-02-19 Πολυμερη συνδεσης πρωτονιου για χορηγηση απο του στοματος

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20201100400T CY1122928T1 (el) 2014-12-10 2020-04-30 Πολυμερη συνδεσης πρωτονιου για χορηγηση απο του στοματος

Country Status (26)

Country Link
US (3) US11311571B2 (el)
EP (3) EP3718551A1 (el)
JP (4) JP6903576B2 (el)
KR (2) KR102625115B1 (el)
CN (2) CN107428955B (el)
AU (2) AU2015360413B2 (el)
BR (2) BR112017011838B1 (el)
CA (3) CA3205149A1 (el)
CY (2) CY1122928T1 (el)
DK (2) DK3229816T3 (el)
ES (2) ES2787218T3 (el)
HK (1) HK1243952A1 (el)
HR (2) HRP20200689T1 (el)
HU (2) HUE049057T2 (el)
IL (3) IL252439B (el)
LT (2) LT3229816T (el)
MA (3) MA41150B1 (el)
MD (2) MD3229816T2 (el)
ME (1) ME03783B (el)
MX (3) MX2017007497A (el)
PL (2) PL3593808T3 (el)
PT (2) PT3593808T (el)
RS (2) RS61409B1 (el)
RU (2) RU2713416C2 (el)
SI (2) SI3229816T1 (el)
WO (1) WO2016094685A1 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3003327T (lt) 2013-06-05 2017-12-27 Tricida Inc. Protonus surišantys polimerai, skirti geriamajam vartojimui
CA3205149A1 (en) 2014-12-10 2016-06-16 Tricida, Inc. Proton-binding polymers for oral administration
IL262660B2 (en) 2016-05-06 2024-04-01 Tricida Inc Preparations for and method of treating acid-base disorders
WO2018124264A1 (ja) 2016-12-28 2018-07-05 富士フイルム株式会社 窒素原子含有ポリマー又はその塩の乳化液、その製造方法、及び粒子の製造方法
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
WO2019078197A1 (ja) 2017-10-16 2019-04-25 富士フイルム株式会社 高リン血症治療剤
WO2019090176A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders
WO2019236636A1 (en) * 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
WO2019236124A1 (en) * 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
EP4053179A1 (en) 2021-03-01 2022-09-07 Tricida Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01100164A (ja) * 1987-10-12 1989-04-18 Shionogi & Co Ltd スルファモイル−２−ベンゾフランカルボン酸誘導体
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US5556619A (en) * 1992-08-20 1996-09-17 The Du Pont Merck Pharmaceutical Company Crosslinked polymeric ammonium salts
CA2202397C (en) 1994-10-17 2002-07-16 Peter W. Stacpoole Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5648355A (en) 1994-02-09 1997-07-15 Kos Pharmaceutical, Inc. Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US20020006899A1 (en) 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
US5753706A (en) 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
JP3952223B2 (ja) * 1997-05-28 2007-08-01 日東紡績株式会社 アリルアミン重合体
AUPO758297A0 (en) 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
US6726905B1 (en) 1997-11-05 2004-04-27 Genzyme Corporation Poly (diallylamines)-based phosphate binders
WO1999040990A1 (en) 1998-02-17 1999-08-19 University Of Maryland Anion binding polymers and the use thereof
US6485703B1 (en) 1998-07-31 2002-11-26 The Texas A&M University System Compositions and methods for analyte detection
US6271264B1 (en) 1998-12-01 2001-08-07 Geltex Pharmaceuticals, Inc. Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
GB9927088D0 (en) 1999-11-17 2000-01-12 Secr Defence Use of poly(diallylamine) polymers
WO2001066607A1 (fr) 2000-03-09 2001-09-13 Hisamitsu Pharmaceutical Co., Inc. Resine echangeuse d'anions reticulee ou sel de celle-ci et adsorbant phosphoreux la contenant
WO2001066606A1 (fr) 2000-03-09 2001-09-13 Hisamitsu Pharmaceutical Co., Inc. Resine echangeuse d'anions reticulee ou sel de celle-ci
EP1283046A1 (en) 2000-03-13 2003-02-12 Hisamitsu Pharmaceutical Co., Inc. Preventives and/or remedies for hyperphosphatemia
JP2002028737A (ja) 2000-07-07 2002-01-29 Fujitsu Ltd プレス打ち抜き加工方法及びプレス打ち抜き加工装置
DE60224052T2 (de) 2001-04-18 2008-11-06 Genzyme Corp., Cambridge Aminpolymere zur behandlung von gicht und zur senkung des harnsäuregehaltes
EP1379258B1 (en) 2001-04-18 2006-06-28 Genzyme Corporation Low salt forms of polyallylamine
EP1483232A1 (en) 2002-03-11 2004-12-08 Novartis AG Salts of nateglinide
CA2514071A1 (en) 2003-02-10 2004-08-19 Autogen Research Pty Ltd Therapeutic molecules
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US7449605B2 (en) 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7767768B2 (en) 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7335795B2 (en) 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7459502B2 (en) 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7608674B2 (en) * 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
AU2004311849B2 (en) 2003-12-31 2009-04-02 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
WO2005072773A1 (ja) 2004-01-29 2005-08-11 Keio University 赤血球機能修飾物質
US8192758B2 (en) * 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US7429394B2 (en) 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
US7854924B2 (en) 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
KR101228233B1 (ko) 2004-03-30 2013-01-31 리립사, 인크. 이온 결합 중합체 및 이의 용도
US8399025B2 (en) 2004-06-04 2013-03-19 Board Of Regents, The University Of Texas System Polyamine modified particles
CA2574360A1 (en) 2004-07-19 2006-01-26 N.V. Nutricia A preparation for use of aspartate for regulating glucose levels in blood
DE102004035808A1 (de) 2004-07-21 2006-03-16 Kasch, Helmut, Dr. Ammoniumsalze und Ammoniumsalz-Mineralsalzchlatrate als Transport- und Wirkform für pharmazeutische-medizinische und als Phasentransfermittel für chemische Anwendungen
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
US20070293429A1 (en) 2004-10-08 2007-12-20 Therapei Pharmaceuticals, Inc. Vasoactive Intestinal Polypeptide Compositions
US20080214440A1 (en) 2004-10-08 2008-09-04 Forbes Medi-Tech (Research), Inc. Vasoactive intestinal polypeptide compositions
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
ITME20040015A1 (it) 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
WO2007004236A2 (en) 2005-07-04 2007-01-11 Ramu Krishnan Improved drug or pharmaceutical compounds and a preparation thereof
EP1931689B1 (en) 2005-08-18 2015-02-25 Panion & BF Biotech Inc. Pharmaceutical-grade ferric citrate for medical use
US8986669B2 (en) 2005-09-02 2015-03-24 Genzyme Corporation Method for removing phosphate and polymer used therefore
BRPI0616604A2 (pt) 2005-09-30 2012-12-25 Ilypsa Inc mÉtodo para remover e composiÇço para seletivamente remover Íon de potÁssio do trato gastrintestinal de um mamÍfero, mÉtodo para seletivamente remover Íon de potÁssio de um meio-ambiente, composiÇço farmacÊutica, partÍcula de nécleo-envoltàrio, e, usos de uma partÍcula de nécleo-envoltàrio e de uma composiÇço farmacÊutica
GB2446076B (en) 2005-09-30 2010-11-24 Ilypsa Inc Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
WO2007038801A2 (en) 2005-09-30 2007-04-05 Ilypsa, Inc. Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
JP2009514966A (ja) 2005-11-08 2009-04-09 ジェンザイム・コーポレーション 高リン血症のためのマグネシウム含有重合体
JP5246398B2 (ja) 2005-11-08 2013-07-24 味の素株式会社 麻酔覚醒促進剤
ITMI20052461A1 (it) 2005-12-22 2007-06-23 Univ Degli Studi Milano Sistemi microparticellari per la somministrazione orale di sostanze biologicamente attive
RU2008136081A (ru) 2006-02-14 2010-03-20 Тева Фармасьютикл Индастриес Лтд. (Il) Фармацевтические составы с алифатическими аминными полимерами и способы их производства
JP2009536246A (ja) 2006-05-05 2009-10-08 ゲンズイメ コーポレーション ホスフェート捕捉剤としてのアミン縮合重合体
EP2043627A2 (en) 2006-07-05 2009-04-08 Genzyme Corporation Iron(ii)-containing treatments for hyperphosphatemia
WO2008011047A2 (en) 2006-07-18 2008-01-24 Genzyme Corporation Amine dendrimers
EP2046284A1 (en) 2006-08-04 2009-04-15 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
US7964182B2 (en) 2006-09-01 2011-06-21 USV, Ltd Pharmaceutical compositions comprising phosphate-binding polymer
RU2009111853A (ru) 2006-09-01 2010-10-10 Юсв Лимитед (In) Способ получения гидрохлорида севеламера и его лекарственной формы
BRPI0716066A2 (pt) 2006-09-01 2013-09-17 Genzyme Corp composiÇço farmacÊutica, mÉtodo para tratar doenÇas, polÍmero de amina, rede polimÉrica, mÉtodo para preparar um polÍmero de amina, e, composto de amina
US7868045B2 (en) 2006-09-06 2011-01-11 Sucampo Ag Method for promoting gastrointestinal bicarbonate secretion
JP2010504975A (ja) 2006-09-29 2010-02-18 ゲンズイメ コーポレーション アミドデンドリマー組成物
BRPI0720234A2 (pt) 2006-12-14 2013-12-24 Genzyme Corp Composição farmacêutica
WO2008103368A1 (en) 2007-02-23 2008-08-28 Genzyme Corporation Amine polymer compositions
US20080207766A1 (en) 2007-02-27 2008-08-28 Agi Therapeutics Research Ltd. Methods and compositions for treating at least one upper gastrointestinal symptom
EP2131820A1 (en) 2007-03-08 2009-12-16 Genzyme Corporation Sulfone polymer compositions
TWI445540B (zh) 2007-04-20 2014-07-21 Ajinomoto Kk 抗低體溫組成物
EP2152277A1 (en) 2007-04-27 2010-02-17 Genzyme Corporation Amido-amine dendrimer compositions
WO2009005838A2 (en) 2007-07-02 2009-01-08 Cognate3 Llc Process for the preparation of a non-corrosive base solution and methods of using same
EP2168992A1 (en) * 2007-07-11 2010-03-31 Toray Industries, Inc. Crosslinked polyallylamine or acid addition salt thereof, and use thereof for medical purposes
EP2016947A1 (en) 2007-07-17 2009-01-21 Chemo Ibérica, S.A. Novel one step process for preparing cross-linked poly(allylamine) polymers
WO2009023544A2 (en) 2007-08-10 2009-02-19 Ilypsa, Inc. Dosage unit anion-exchange polymer pharmaceutical compositions
US20090125433A1 (en) * 2007-11-13 2009-05-14 Franck Rene Mikulecz Best pre-match routing (of foreign exchange orders)
US20090156647A1 (en) 2007-12-12 2009-06-18 Iovate T. & P. Inc. Method for maintaining physiological pH levels during intensive physical exercise
PA8807201A1 (es) 2007-12-14 2009-07-23 Genzyme Corp Composiciones farmaceuticas
US20100316589A1 (en) 2007-12-14 2010-12-16 Hitesh Bhagat Coated Pharmaceutical Compositions
JP2009179724A (ja) * 2008-01-31 2009-08-13 Toray Ind Inc 架橋ポリビニルアミン又はその酸付加塩、及びその医薬用途
WO2009097127A1 (en) 2008-01-31 2009-08-06 Genzyme Corporation Pharmaceutical compositions
CN102307578B (zh) 2008-03-11 2016-05-04 利维昂尼克斯公司 治疗炎症和炎症相关疾病的方法和组合物
BRPI0911041A2 (pt) * 2008-04-08 2016-07-05 Usv Ltd processo para a preparação de sal de polímero de amina
BRPI0822017A2 (pt) 2008-04-11 2015-07-21 Gp Investimenti S R L Manopla para tratamento de ultrassom em tecido humano.
WO2009154747A1 (en) 2008-06-20 2009-12-23 Genzyme Corporation Pharmaceutical compositions
DE102008030046A1 (de) 2008-06-25 2009-12-31 Ratiopharm Gmbh Kompaktiertes Polyallylamin-Polymer
US20100008988A1 (en) 2008-07-14 2010-01-14 Glenmark Generics, Ltd. Tablet compositions of amine polymers
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US8337824B2 (en) 2008-08-22 2012-12-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
US20100104527A1 (en) 2008-08-22 2010-04-29 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
CN105309424B (zh) 2008-09-25 2022-09-02 维乌作物保护有限公司 生产聚合物纳米颗粒的方法和活性成分的制剂
US20110268666A1 (en) 2008-09-29 2011-11-03 Yissum Research Development Company of the Research University of Jerusalem, Ltd. Novel gastroretentive delivery system
US20100113479A1 (en) 2008-10-30 2010-05-06 Anusuya Choudhury Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists
US20100166861A1 (en) 2008-12-29 2010-07-01 Kelly Noel Lynch Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone
MX2011007760A (es) 2009-01-22 2011-08-17 Usv Ltd Composiciones farmaceuticas que comprenden polimero vinculante a fosfato.
CA2777682C (en) 2009-10-13 2015-02-24 The Regents Of The University Of Michigan Dendrimer compositions and methods of synthesis
EA024699B1 (ru) 2009-10-22 2016-10-31 Синтон Б. В. Фармацевтическая таблетка с немедленным высвобождением, содержащая севеламера карбонат
JP5984675B2 (ja) 2009-12-07 2016-09-06 アイアンウッド ファーマシューティカルズ インコーポレイテッド 胃腸障害の療法
CN105017481B (zh) 2010-02-24 2018-10-02 瑞立普萨公司 用作胆汁酸螯合剂的交联聚乙烯胺、聚烯丙胺和乙烯亚胺
WO2011106545A1 (en) 2010-02-24 2011-09-01 Relypsa, Inc. Polyimidazoles for use as bile acid sequestrants
IT1406068B1 (it) 2010-07-22 2014-02-06 Medestea Int Spa Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
KR101238210B1 (ko) 2011-06-30 2013-03-04 엘지전자 주식회사 이동 단말기
US20130137772A1 (en) 2011-11-29 2013-05-30 Raymond J. Bergeron Hydroxypolyamine salts
EP3730136B1 (en) 2012-06-21 2023-12-27 Keryx Biopharmaceuticals, Inc. Use of ferric citrate in the treatment of chronic kidney disease patients
KR20150088243A (ko) 2012-10-08 2015-07-31 리립사, 인크. 고혈압 및 고칼륨혈증을 치료하기 위한 칼륨-결합제
LT3003327T (lt) 2013-06-05 2017-12-27 Tricida Inc. Protonus surišantys polimerai, skirti geriamajam vartojimui
CA2928200A1 (en) 2013-11-04 2015-05-07 Keryx Biopharmaceuticals, Inc. Ferric citrate for reducing cardiac failure in chronic kidney disease patients
CA3205149A1 (en) 2014-12-10 2016-06-16 Tricida, Inc. Proton-binding polymers for oral administration
IL262660B2 (en) 2016-05-06 2024-04-01 Tricida Inc Preparations for and method of treating acid-base disorders
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
CA3080143A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Method of treating acid-base disorders
WO2019090176A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders
WO2019236639A1 (en) 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
WO2019236636A1 (en) 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
WO2019236124A1 (en) 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
US20200306209A1 (en) 2019-03-27 2020-10-01 Tricida, Inc. Method of treating acid-base disorders

Also Published As

Publication number Publication date
HRP20200689T1 (hr) 2020-07-24
HK1243952A1 (zh) 2018-07-27
AU2015360413A1 (en) 2017-06-08
BR112017011838B1 (pt) 2023-04-25
ES2857177T3 (es) 2021-09-28
CY1122928T1 (el) 2021-10-29
HRP20210204T1 (hr) 2021-03-19
KR102625115B1 (ko) 2024-01-12
SI3593808T1 (sl) 2021-03-31
PL3593808T3 (pl) 2021-06-14
DK3229816T3 (en) 2020-04-27
CN113855703A (zh) 2021-12-31
JP2020158530A (ja) 2020-10-01
US20220339186A1 (en) 2022-10-27
WO2016094685A1 (en) 2016-06-16
MA48486B1 (fr) 2021-03-31
HUE052736T2 (hu) 2021-05-28
SI3229816T1 (sl) 2020-09-30
IL290729A (en) 2022-04-01
CA2969238C (en) 2023-10-17
PL3229816T3 (pl) 2020-09-21
DK3593808T3 (da) 2021-02-01
MD3593808T2 (ro) 2021-05-31
CN107428955A (zh) 2017-12-01
KR20240008418A (ko) 2024-01-18
MX2017007497A (es) 2017-10-04
JP6903576B2 (ja) 2021-07-14
JP7258087B2 (ja) 2023-04-14
MA48486A (fr) 2020-01-15
LT3229816T (lt) 2020-05-25
IL278034A (en) 2020-11-30
EP3718551A1 (en) 2020-10-07
CA3205149A1 (en) 2016-06-16
MA53106A (fr) 2021-09-15
CA2969238A1 (en) 2016-06-16
BR122021001914B1 (pt) 2024-02-27
PT3229816T (pt) 2020-05-11
CA3164664A1 (en) 2016-06-16
AU2015360413B2 (en) 2021-07-08
KR20170095269A (ko) 2017-08-22
MX2019014711A (es) 2020-02-12
JP6921276B2 (ja) 2021-08-18
EP3593808A1 (en) 2020-01-15
RU2713416C2 (ru) 2020-02-05
EP3229816B1 (en) 2020-02-05
AU2021245144B2 (en) 2024-01-11
RU2017124157A (ru) 2019-01-10
JP2021176971A (ja) 2021-11-11
JP2017538822A (ja) 2017-12-28
MD3229816T2 (ro) 2020-07-31
ES2787218T3 (es) 2020-10-15
JP7536343B2 (ja) 2024-08-20
MA41150B1 (fr) 2020-06-30
HUE049057T2 (hu) 2020-08-28
IL252439A0 (en) 2017-07-31
RS60208B1 (sr) 2020-06-30
RU2017124157A3 (el) 2019-07-17
US11311571B2 (en) 2022-04-26
LT3593808T (lt) 2021-02-25
CN107428955B (zh) 2021-09-21
RS61409B1 (sr) 2021-03-31
EP3229816A1 (en) 2017-10-18
US20230405043A1 (en) 2023-12-21
US11738041B2 (en) 2023-08-29
PT3593808T (pt) 2021-02-11
US20180021370A1 (en) 2018-01-25
IL278034B (en) 2022-04-01
AU2021245144A1 (en) 2021-11-04
MA41150A (fr) 2017-10-18
ME03783B (me) 2021-04-20
IL252439B (en) 2020-10-29
JP2023085428A (ja) 2023-06-20
MX2021004558A (es) 2022-05-03
BR112017011838A2 (pt) 2017-12-26
EP3593808B1 (en) 2020-12-09
RU2020102937A (ru) 2020-02-13

Similar Documents

Publication Publication Date Title
CY1123673T1 (el) Πολυμερη συνδεσης πρωτονιου για χορηγηση απο του στοματος
CY1124073T1 (el) Πολυμερη συνδεσης πρωτονιου για χορηγηση απο του στοματος
MY197091A (en) Compositions for treating acid-base disorders
CY1119123T1 (el) Δις-αρυλοσυζευγμενες αρυλοτριαζολονες και η χρηση τους
CY1125089T1 (el) Μεθοδοι για τη θεραπεια μολυνσεων απο coronaviridae
CY1122642T1 (el) Αντι-β7-η1 και anti-ctla-4 αντισωματα για τη θεραπευτικη αγωγη μη μικροκυτταρικου πνευμονικου καρκινου
CY1122078T1 (el) Θεραπευτικα νανοσωματιδια που εμπεριεχουν θεραπευτικο παραγοντα και μεθοδοι παρασκευης και χρησης αυτων
CY1121736T1 (el) Άλατα aramchol
EA201790174A1 (ru) Антипролиферативные соединения и способы их применения
MA52909A (fr) Procédés d'augmentation des taux de globules rouges et de traitement de la drépanocytose
CY1122805T1 (el) Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
CY1123216T1 (el) Αναστολεις της gls1 για την αντιμετωπιση νοσων
CY1120835T1 (el) Ταυρο-ουρσοδεοξυχολικο οξυ (tudca) για χρηση στη θεραπεια νευροεκφυλιστικων διαταραχων
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
CY1114757T1 (el) Παραγωγα οξαζινης και η χρηση τους στη θεραπεια νευρολογικων διαταραχων
BR112017002878A2 (pt) distribuição coordenada de tratamento de copd
UA112488C2 (uk) Три(гетеро)арилпіразоли і їх застосування
BR112017011490A2 (pt) método para tratar condição inflamatória ou isquêmica em um órgão ou tecido de um paciente
CY1120381T1 (el) Μεθοδος για την αγωγη και τη θεραπεια της λεϊσμανιασης δια της χρησεως φεξινιδαζολης
RU2012100120A (ru) Акарицидная фармацевтическая композиция на основе соли четвертичного фосфония, замещенного динитробензофураксана и ксимедонгидрохлорида
MX367120B (es) Pinzas para reparación percutánea del tendón de aquiles por mínima invasión.
CY1121354T1 (el) Μεθοδοι θεραπευτικης αντιμετωπισης ή προληψης του ασθματος μεσω χορηγησης ανταγωνιστη il-4r
CY1121264T1 (el) Εστερες στεροειδικης λακταμης και παραγωγα αμφι(2-χλωροαιθυλ)-αμινοφαινοξυ-προπανοϊκου οξεος
CY1124859T1 (el) Ομοδιμερικο πεπτιδιο για τη θεραπεια του διαβητη και σχετικων νοσων